Moxifloxacin suppresses airway inflammation and modulates expression of caveolin-1 and flotillin-1 in airway smooth muscle cells of asthmatic rats.

Background: Moxifloxacin (MXF) possesses anti-inflammatory properties on asthmatic airway smooth muscle cells (ASMCs) beyond their antimicrobial effects, but the mechanisms are still unknown. This study was to investigate effects of MXF on expression of caveolin-1 (Cav-1) and flotillin-1 (FLOT1) in ASMCs in asthmatic rats. Methods: ASMCs were collected from the airway and cultured in vitro. Cells from normal rats were treated with normal saline (Group N); cells from asthmatic rats were incubated with normal saline (Group A) or MXF (20 mg/L) (Group M); Cav-1 expression was up-regulated by transferring Cav-1 expressing lentivirus (Group L) and FLOT1 expression down-regulated by using siRNA in cells from asthmatic rats (Group S). The expressions of Cav-1, FLOT1 and p65 NF-kappa B were measured by Western blotting and quantificational real-time polymerase chain reaction (qRT-PCR), and interleukin-8 (IL-8) and eotaxin contents were measured by enzyme-linked immunosorbent assay (ELISA). Results: Compared with normal control, Cav-1 expression significantly decreased in asthmatic groups (P< 0.01); MXF up-regulated Cav-1 expression in asthmatic groups (P< 0.01). However, compared with normal control, the expression of FLOT1 and p65 NF-kappa B dramatically increased in asthmatic groups (P< 0.01); MXF down-regulated the expression of FLOT1 and p65 NF-kappa B in asthmatic groups (P< 0.01); meanwhile, the expressions of FLOT1 and p65 NF-kappa B decreased after up-regulation of Cav-1 expression in asthmatic groups (P= 0.01). Compared with asthmatic groups, the IL-8 and eotaxin contents significantly decreased in MXF Groups, Cav-1 up-regulation asthmatic groups and FLOT1 down-regulation asthmatic groups (P< 0.01). Conclusions: MXF can modulate the airway inflammation, upregulate Cav-1 expression, downregulate the expression of FLOT1 and p65 NF-kappa B in asthmatic rat ASMCs, which may be related to the antiinflammatory effects of MXF in asthmatic ASMCs.